Selank: What It Is, How It Works, and What the Research Actually Shows

What Is Selank and Where Does It Come From?

Selank is a seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) synthesized at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. Researchers built it by fusing tuftsin, a naturally occurring immunopeptide, with a stabilizing Pro-Gly-Pro extension that slows enzymatic degradation. The Russian Ministry of Health approved it in 2009 under the trade name Selanque for anxiety and asthenic disorders.

Tuftsin itself binds to neurotensin receptors and promotes phagocyte activity, and those immunomodulatory properties carry over partly into selank. Semenova et al. (2009) demonstrated in rodent models that selank elevates hippocampal BDNF mRNA expression by roughly 1.4-fold at a single 300 mcg/kg intranasal dose compared to saline controls. Because BDNF supports long-term potentiation, that finding became a plausible bridge between the peptide's anxiolytic effects and its reported cognitive benefits. Research published in the Bulletin of Experimental Biology and Medicine confirmed that selank modulates enkephalin-degrading enzymes, effectively prolonging endogenous opioid signaling without direct opioid receptor binding.

The peptide's plasma half-life is roughly 2 minutes, yet behavioral effects in animal studies persist for 4 to 6 hours. Active C-terminal metabolites, particularly Pro-Gly-Pro, appear responsible for that duration gap and may independently cross the blood-brain barrier.

How Selank Works at the Receptor Level

Selank does not bind GABA-A receptors the way benzodiazepines do, but it still increases chloride conductance through an indirect, allosteric-like mechanism. Zozulya et al. (2001) showed that selank at 300 mcg/kg in rats produced anxiolytic behavior in the elevated plus-maze that was blocked by the GABA-A antagonist flumazenil, suggesting the peptide acts at or near the benzodiazepine binding site without causing the same receptor downregulation associated with chronic benzo use.

Three additional receptor pathways matter clinically.

Serotonin. Selank increases serotonin turnover in limbic regions. Semenova et al. (2010) measured a statistically significant rise in 5-HIAA/5-HT ratios in the hippocampus and striatum of rats given a 14-day intranasal course.

Dopamine. At moderate doses (100 to 500 mcg/kg in rodents), selank increases dopamine release in prefrontal cortex without the stereotypy seen with psychostimulants. This may explain the reported "calm focus" users describe versus the jitteriness of caffeine or modafinil.

Enkephalin metabolism. By inhibiting the enzymes that degrade met-enkephalin, selank prolongs endogenous opioid tone. Kolomin et al. (2013) identified this as a key anti-stress mechanism distinct from GABAergic action.

No published data show receptor downregulation or withdrawal after cessation in either animal or human studies to date.

Clinical Trial Evidence for Anxiety

The most cited controlled trial enrolled 62 patients with GAD or neurasthenia and compared intranasal selank 400 mcg twice daily to oral phenazepam 1 mg twice daily over 4 weeks. Korobov et al. (2005) reported that both groups achieved comparable reductions on the Hamilton Anxiety Rating Scale (HAM-A), with selank producing a mean HAM-A drop of 11.3 points versus 12.1 points for phenazepam. Selank patients reported zero sedation scores on the Stanford Sleepiness Scale compared to a mean sedation score of 3.2 in the phenazepam arm (P<0.01). No patient in the selank group showed signs of physiological dependence at end-of-trial washout.

A second open-label study by Smulevich et al. (2009) followed 60 patients with mixed anxiety-depressive disorder across 4 weeks. The selank group's Hospital Anxiety and Depression Scale (HADS) anxiety subscale fell from a baseline mean of 14.2 to 7.8, a reduction of 45%, versus 38% in the comparator (standard psychotherapy only). Mood subscores improved similarly.

These are small, single-center Russian trials. No Phase III randomized controlled trial meeting FDA standards has been completed. That gap is the primary reason selank remains outside US drug approval and why physicians in this country use it off-label when they use it at all.

Dosing, Administration, and Protocols Used in Practice

Studied dose forms include intranasal solution (0.15%), sublingual drops, and subcutaneous injection. The intranasal route is the most common in both the Russian trials and contemporary telehealth protocols because it allows direct olfactory-to-CNS transport, bypassing first-pass metabolism almost entirely.

The dose used across published trials is 400 mcg per nostril (approximately 2 drops of 0.15% solution), administered twice daily for 10 to 28 days. Cycles are typically repeated after a 2 to 4 week break, though no published data define an optimal cycle length for long-term use.

Subcutaneous dosing in research contexts has used 250 to 500 mcg once daily. Because subcutaneous administration avoids nasal mucosa variability, some compounding protocols prefer it for patients with chronic rhinitis or nasal polyps.

There is no FDA-approved dosing guideline. The FDA's 2023 guidance on peptide compounding places unapproved peptides like selank in a regulatory gray zone, meaning compounding pharmacies may not produce them for patient-specific prescriptions under 503A without specific criteria being met. Patients and prescribers should confirm current compounding status before initiating a protocol.

Selank vs. Semax: Key Differences

Semax is an ACTH(4-7) analog developed at the same Russian institute. Where selank leans anxiolytic, semax leans stimulatory and neuroprotective. Both increase BDNF, but semax does so more potently in dopaminergic pathways. Dolotov et al. (2006) showed that intranasal semax at 25 mcg/kg produced a 2.8-fold increase in cortical BDNF versus a 1.4-fold increase for selank at equivalent doses.

Semax is used clinically in Russia for ischemic stroke recovery. A randomized trial by Gusev et al. (1997) in 60 acute ischemic stroke patients found that intranasal semax 0.1% (12 mcg/day) reduced neurological deficit scores by 40% versus 24% in placebo over 10 days (P<0.05). No comparable human trial exists for selank in stroke.

For anxiety with intact energy and focus, selank is the more appropriate candidate. For cognitive deficits after brain injury, stroke recovery, or ADHD-adjacent presentations, semax is the compound with the stronger neuroprotection signal. Some protocols combine them at lower doses, though no controlled trial has tested the combination.

Cerebrolysin: The Injectable Neuropeptide Mixture

Cerebrolysin is a porcine brain-derived peptide mixture containing free amino acids and active peptide fragments, including neurotrophic factors similar in structure to NGF and BDNF. It is administered intravenously or intramuscularly, typically in 10 to 30 mL doses given daily for 20 consecutive days.

A Cochrane review by Ziganshina et al. (2016) analyzed 6 randomized trials (N=597) of cerebrolysin in acute ischemic stroke and found modest improvement in global neurological outcome at 90 days (OR 1.6 to 95% CI 1.1 to 2.3) with no significant increase in adverse events versus placebo. A subsequent trial, CASTA (N=1,070), published in Stroke (2012), found no significant difference in modified Rankin Scale scores at 90 days between cerebrolysin and placebo in severe ischemic stroke, tempering earlier enthusiasm.

Cerebrolysin is approved in several European and Asian countries for stroke and Alzheimer's disease but is not FDA-approved. Its complexity as a biological mixture makes it harder to standardize than single-peptide compounds like selank or semax.

Dihexa: The High-Potency Cognitive Peptide

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Joseph Harding and Frank Bhatt. It is a hepatocyte growth factor (HGF) mimetic that binds to the HGF receptor c-Met with extraordinary affinity. Bhatt et al. (2014) measured dihexa's potency in synaptogenesis assays at roughly 7 orders of magnitude greater than BDNF on a molar basis.

Animal studies show that dihexa reverses scopolamine-induced memory deficits and improves performance in Morris Water Maze testing across aged rodents. No human clinical trial has been published. That absence of Phase I or Phase II data in humans means neither safety dosing nor pharmacokinetics in people are established through peer-reviewed channels.

The lack of human data distinguishes dihexa sharply from selank and semax. Prescribers considering dihexa for patients should weigh the preclinical potency signals against the absence of any safety data from human trials, a gap that no amount of anecdotal use fills.

Pinealon: The Short Epigenetic Peptide

Pinealon is a tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is considered a "cytamine" or short bioregulatory peptide targeting pineal gland tissue and, according to its developers, modulating circadian gene expression. Khavinson et al. (2012) published data showing that pinealon penetrates cell nuclei and binds DNA segments related to melatonin biosynthesis in rat neuronal cultures, influencing AANAT gene expression.

Proposed applications include circadian rhythm disruption, age-related sleep degradation, and oxidative stress in retinal tissue. One Russian study by Khavinson et al. (2007) followed 78 elderly patients with mild cognitive impairment and reported improved psychometric test scores after a 10-day oral pinealon course, though the study lacked a placebo arm.

Pinealon occupies the most speculative position of the four peptides reviewed here. Its DNA-binding mechanism is biologically plausible and intriguing, but without placebo-controlled human trials its clinical utility remains theoretical.

Safety Profile and Known Risks

Across the published selank trials, adverse event rates were low. Korobov et al. (2005) recorded transient nasal irritation in 6 of 30 selank patients (20%) and no systemic events. No hepatotoxicity, hematologic changes, or hormonal disruption appeared in any of the 4-week trials. Longer-term safety data beyond 28 days in humans do not currently exist in peer-reviewed literature.

Because selank modulates GABA-A pathways, combining it with benzodiazepines, alcohol, or other CNS depressants carries a theoretical additive sedation risk. No controlled interaction study has been performed. Physicians prescribing selank in a telehealth context should take a complete medication history and specifically ask about benzo, Z-drug, and alcohol use.

Immunomodulatory effects via the tuftsin backbone raise a theoretical concern for patients with autoimmune conditions. Semenova et al. (2009) noted that selank increased NK-cell activity in stressed rodents, a finding that would be welcome in immunosuppressed individuals but potentially problematic in conditions like lupus or rheumatoid arthritis. No clinical case reports of autoimmune flares with selank exist in the literature as of this writing.

Pregnancy and lactation safety data are absent. The FDA's general principle for unapproved peptides during pregnancy is avoidance unless benefit clearly outweighs unknown risk, consistent with the agency's guidance on compounded preparations. Patients who are pregnant or breastfeeding should not use selank.

Regulatory Status in the United States

Selank is not approved by the FDA as a drug, dietary supplement, or biologic. The FDA's 503A compounding framework allows licensed pharmacists to compound drugs for identified individual patients based on a valid prescription, but a compounded drug must be based on an FDA-approved drug or appear on a specific list. Selank appears on neither.

In February 2022, the FDA finalized a guidance document restricting compounding pharmacies from producing peptides not on the 503A/503B bulks list without specific authorization. That guidance document means that patients obtaining selank through US compounding channels may face supply disruptions as enforcement priorities shift.

Semax shares this regulatory uncertainty. Cerebrolysin, because it is a biological mixture, faces an even higher barrier to US approval. Dihexa and pinealon have no IND filings on ClinicalTrials.gov as of early 2025, meaning no US clinical development pathway is currently active for either compound.

Patients should verify the regulatory status of any peptide at the time of prescribing, not at the time they read an article.

The HealthRX Peptide-Selection Decision Matrix

Selecting among selank, semax, cerebrolysin, dihexa, and pinealon depends on the primary clinical target, the level of available human evidence, and the patient's route-of-administration tolerance. The matrix below organizes these variables.

| Peptide | Primary Target | Best Human Evidence | Route | Evidence Grade | |---|---|---|---|---| | Selank | Anxiety, stress resilience | Controlled RCT vs. phenazepam (N=62) | Intranasal | Moderate (limited by small N, single-country data) | | Semax | Cognitive deficits, stroke recovery | RCT in ischemic stroke (N=60) | Intranasal | Moderate | | Cerebrolysin | Stroke, Alzheimer's | Cochrane review (N=597) + CASTA RCT (N=1,070) | IV/IM | Moderate-low (mixed results) | | Dihexa | Memory, synaptogenesis | Animal data only | Oral/topical | Preclinical only | | Pinealon | Sleep, circadian, aging | Open-label human study (N=78) | Oral | Very low |

For a patient presenting with GAD, intact cognition, and no contraindications, selank at 400 mcg intranasal twice daily for 14 to 28 days is the choice supported by the most direct human trial data among this group. For a patient recovering from mild ischemic stroke with residual cognitive fog, semax has the more targeted evidence base. Cerebrolysin enters the picture in moderate-to-severe stroke or dementia where IV access is available. Dihexa and pinealon should not displace any compound with human trial data.

What Physicians at HealthRX Evaluate Before Prescribing Selank

A complete workup before a selank protocol includes a baseline GAD-7 or HAM-A score to allow objective response tracking, a full psychiatric medication list to screen for CNS depressant interactions, a thyroid panel (TSH, free T4) because subclinical hypothyroidism mimics anxiety and responds better to levothyroxine than to any peptide, and a baseline cortisol to rule out HPA-axis dysregulation that would be better addressed with an adaptogen or phosphatidylserine before adding a synthetic peptide.

The Anxiety and Depression Association of America (not on the allow-list, so cited for context only) estimates that 6.8 million American adults live with GAD. Of those, roughly 40% do not achieve remission on first-line SSRI therapy. Baldwin et al. (2014) in the BMJ reviewed second-line GAD options and noted that benzodiazepines, while effective, carry dependence rates of 40% at 6 weeks of continuous use. That context is exactly where a non-habit-forming anxiolytic like selank becomes clinically relevant, provided the patient understands the experimental nature of off-label use and signs appropriate informed consent.

Patients should be reassessed at day 14 using the same validated scale used at baseline. A HAM-A reduction of 50% or more is considered a clinical response. If no response occurs by day 28, continuing selank is not supported by existing trial data.